News | June 09, 2023
Lonza signs VPPA for solar power supply with Ignis
Under the terms of the VPPA, IGNIS will produce renewable energy equal to Lonza’s electricity needs across Switzerland and the European Union.
Under the terms of the VPPA, IGNIS will produce renewable energy equal to Lonza’s electricity needs across Switzerland and the European Union.
New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Establishes distribution center in top hub for international shipping
European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
The target boundary includes biogenic land?related emissions and removals from bioenergy feedstock
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
The project is part of a three-year-long partnership between Honeywell and Americares to strengthen the health infrastructure in rural Maharashtra, Uttarakhand and Haryana
Subscribe To Our Newsletter & Stay Updated
